ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Solasia enters new license alliance with Maruho biospectrumasia
December 12, 2019Japan based Solasia Pharma K.K. has announced that it has entered into an exclusive license agreement with Maruho Co., Ltd. for the commercialization of Solasia’s product SP-04 (PledOx?), a therapeutic agent for chemotherapy induced peripheral neuropathy -
Solasia initiates Phase III programme for PledOx biospectrumasia
January 07, 2019In November 2017, Solasia acquired exclusive development and commercialization rights for PledOx in Japan, Mainland China, Hong Kong, S.A.R., China Region in China, Macau, S.A.R., China Region in China, Taiwan, China Region in China, South Korea and from -
Solasia announces Episil approval in Japan
biospectrumasia
July 11, 2017Episil oral liquid is the first approved product in Japan for local treatment of pain associated with oral mucositis (OM) for cancer patients undergoing chemotherapy and radiotherapy.
Pharma Sources Insight January 2025
